Jiangbo Pharmaceuticals, Inc. to Present at CCG IR’s China Rising Conference in New York
LAIYANG, China,
Pharmaceuticals, Inc., (OTC Bulletin Board: JGBO; “Jiangbo” or the “Company”)
(which recently changed its name from Genesis Pharmaceuticals Enterprises,
Inc.; OTC Bulletin Board: GNPH), a U.S. pharmaceutical company with its
principal operations in
that its management will present at the upcoming China Rising Conference
hosted by CCG Investor Relations in
The date, time and location of Jiangbo Pharmaceuticals, Inc. presentation
at the China Rising Conference are:
Date: Monday, May 18, 2009
Time: 9:30 a.m. to 10:00 a.m. Eastern Time
Presenter: Ms Elsa Sung, Chief Financial Officer
Venue: The Yale Club
50 Vanderbilt Avenue
New York, NY 10017
Webcast: http://www.chinarisingconference.com/webcast.html
A replay of the webcast will be available for up to one year following the
presentation using the same link.
The China Rising Investment Conference is hosted by CCG Investor Relations
and will provide over 250 fund managers and investors access to senior
management from a wide range of Chinese growth companies in sectors including
consumer staples, agriculture, pharmaceuticals, infrastructure, information
technology, advanced materials, capital goods, and alternative energy. The
conference will include over 30 US-listed Chinese companies and a number of
private companies.
Interested parties and investors can find more information for the
conference by visiting CCG’s
http://www.chinarisingconference.com .
About Jiangbo Pharmaceuticals, Inc.
Jiangbo Pharmaceuticals, Inc. is a U.S. public company engaged in the
research, development, production, marketing and sales of pharmaceutical
products in
province. Jiangbo is a major pharmaceutical company in China producing both
western and Chinese herbal-based medical drugs in tablet, capsule, granule,
and electuary (sticky syrup) form.
Safe Harbor Statement
Certain statements in this press release that are not historical facts are
“forward-looking statements” within the meaning of the Private Securities
Litigation Reform Act of 1995. Such statements are not guarantees of future
performance and are subject to risks and uncertainties that could cause the
Company’s actual results and financial position to differ materially from
those included within the forward-looking statements. Forward-looking
statements involve risks and uncertainties. Actual results may differ
materially from anticipated or predicted results, and reported results should
not be considered as an indication of future performance. The potential risks
and uncertainties include, among others, the Company’s ability to obtain raw
materials needed in manufacturing, the continuing employment of key employees,
the failure risks inherent in testing any new drug, the possibility that
regulatory approvals may be delayed or become unavailable, patent or licensing
concerns that may include litigation, direct competition from other
manufacturers and product obsolescence. More information about the potential
factors that could affect the Company’s business and financial results is
included in the Company’s filings, available via the United States Securities
and Exchange Commission.
For more information, please contact:
Company Contact:
Ms. Elsa Sung, CFO
Jiangbo Pharmaceuticals, Inc.
Tel: +1-954-727-8435
Email: elsasung@jiangbo.com
Website: http://www.jiangbopharma.com/
Investor Relations Contact:
Mr. Crocker Coulson, President
CCG Investor Relations
Tel: +1-646-213-1915 (NY office)
Email: crocker.coulson@ccgir.com
Graham Reed, Financial Writer
Tel: +1-646-213-1907
Email: graham.reed@ccgir.com
Website: http://www.ccgirasia.com
SOURCE Jiangbo Pharmaceuticals, Inc.